182 related articles for article (PubMed ID: 11922858)
21. [Topiramate in substance-related and addictive disorders].
Cohen J; Dervaux A; Laqueille X
Presse Med; 2014 Sep; 43(9):892-901. PubMed ID: 25027463
[TBL] [Abstract][Full Text] [Related]
22. Pergolide mesylate. Adverse events occurring in the treatment of cocaine dependence.
Malcolm R; Moore JW; Kajdasz DK; Cochrane CE
Am J Addict; 1997; 6(2):117-23. PubMed ID: 9134073
[TBL] [Abstract][Full Text] [Related]
23. Medications for stimulant abuse: agonist-based strategies and preclinical evaluation of the mixed-action D-sub-2 partial agonist aripiprazole (Abilify).
Bergman J
Exp Clin Psychopharmacol; 2008 Dec; 16(6):475-83. PubMed ID: 19086768
[TBL] [Abstract][Full Text] [Related]
24. Mechanisms of antiaddictive actions of ibogaine.
Glick SD; Maisonneuve IS
Ann N Y Acad Sci; 1998 May; 844():214-26. PubMed ID: 9668680
[TBL] [Abstract][Full Text] [Related]
25. Pharmacological treatment of cocaine dependence: a systematic review.
de Lima MS; de Oliveira Soares BG; Reisser AA; Farrell M
Addiction; 2002 Aug; 97(8):931-49. PubMed ID: 12144591
[TBL] [Abstract][Full Text] [Related]
26. Clinical trials of pharmacologic treatments in pregnant women--methodologic considerations.
Schottenfeld RS
NIDA Res Monogr; 1995; 149():201-23. PubMed ID: 8775841
[No Abstract] [Full Text] [Related]
27. Treatment of patients with substance use disorders, second edition. American Psychiatric Association.
Kleber HD; Weiss RD; Anton RF; George TP; Greenfield SF; Kosten TR; O'Brien CP; Rounsaville BJ; Strain EC; Ziedonis DM; Hennessy G; Connery HS; McIntyre JS; Charles SC; Anzia DJ; Cook IA; Finnerty MT; Johnson BR; Nininger JE; Summergrad P; Woods SM; Yager J; Pyles R; Cross CD; Peele R; Shemo JP; Lurie L; Walker RD; Barnovitz MA; Gray SH; Saxena S; Tonnu T; Kunkle R; Albert AB; Fochtmann LJ; Hart C; Regier D; ; ;
Am J Psychiatry; 2007 Apr; 164(4 Suppl):5-123. PubMed ID: 17569411
[No Abstract] [Full Text] [Related]
28. A review of the effects of dopaminergic agents on humans, animals, and drug-seeking behavior, and its implications for medication development. Focus on GBR 12909.
Rothman RB; Glowa JR
Mol Neurobiol; 1995; 11(1-3):1-19. PubMed ID: 8561954
[TBL] [Abstract][Full Text] [Related]
29. Development of immunopharmacotherapy against drugs of abuse.
Meijler MM; Matsushita M; Wirsching P; Janda KD
Curr Drug Discov Technol; 2004 Jan; 1(1):77-89. PubMed ID: 16472221
[TBL] [Abstract][Full Text] [Related]
30. Pergolide and Parkinson's disease: new preparation. No clear benefit.
Prescrire Int; 2000 Dec; 9(50):177-9. PubMed ID: 11475497
[TBL] [Abstract][Full Text] [Related]
31. GABA(B) receptor agonists for the treatment of drug addiction: a review of recent findings.
Cousins MS; Roberts DC; de Wit H
Drug Alcohol Depend; 2002 Feb; 65(3):209-20. PubMed ID: 11841892
[TBL] [Abstract][Full Text] [Related]
32. Dopamine D
Hernández-Huerta D; Morillo-González J
CNS Spectr; 2021 Oct; 26(5):444-445. PubMed ID: 32594931
[No Abstract] [Full Text] [Related]
33. The Role of Dopamine D3 Receptors in Tobacco Use Disorder: A Synthesis of the Preclinical and Clinical Literature.
Butler K; Le Foll B; Di Ciano P
Curr Top Behav Neurosci; 2023; 60():203-228. PubMed ID: 36173599
[TBL] [Abstract][Full Text] [Related]
34. Cocaine abuse and adult attention deficit disorder.
Cocores JA; Davies RK; Mueller PS; Gold MS
J Clin Psychiatry; 1987 Sep; 48(9):376-7. PubMed ID: 3624209
[TBL] [Abstract][Full Text] [Related]
35. Dopamine agonists for cocaine dependence.
Soares BG; Lima MS; Reisser AA; Farrell M
Cochrane Database Syst Rev; 2001; (4):CD003352. PubMed ID: 11687193
[TBL] [Abstract][Full Text] [Related]
36. [Tobacco use and illicit substance use disorders: what should we have to do?].
Karila L; Petit A; Zarmdini R; Coscas S; Lowenstein W; Reynaud M
Presse Med; 2013 May; 42(5):795-805. PubMed ID: 23528335
[TBL] [Abstract][Full Text] [Related]
37. Dopamine D3 receptor ligands block nicotine-induced conditioned place preferences through a mechanism that does not involve discriminative-stimulus or antidepressant-like effects.
Le Foll B; Sokoloff P; Stark H; Goldberg SR
Neuropsychopharmacology; 2005 Apr; 30(4):720-30. PubMed ID: 15562293
[TBL] [Abstract][Full Text] [Related]
38. Recent developments in the pharmacotherapy of substance abuse.
O'Brien CP
J Consult Clin Psychol; 1996 Aug; 64(4):677-86. PubMed ID: 8803357
[TBL] [Abstract][Full Text] [Related]
39. Role of dopamine receptor agonists in the treatment of early Parkinson's disease.
Bonuccelli U; Del Dotto P; Rascol O
Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S44-53. PubMed ID: 20123557
[TBL] [Abstract][Full Text] [Related]
40. Are dopamine receptor agonists neuroprotective in Parkinson's disease?
Le WD; Jankovic J
Drugs Aging; 2001; 18(6):389-96. PubMed ID: 11419913
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
